The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Broad Institute

FEBRUARY 29, 2024

By Leah Eisenstadt February 29, 2024 Credit: Courtesy of (clockwise, from top left) National Park Service; Rainer Zenz, Creative Commons license; Len Charnoff/Flickr, public domain; Riki7, public domain; National Park Service; Rufus46, Creative Commons. The work appears in Proceedings of the National Academy of Sciences (PNAS).

Hospitals 116

Hospitals Medical Schools International Research 116

The Pharma Data

MAY 5, 2022

Today, 30-60% of patients with GvHD do not respond to first-line steroid treatment, underscoring the need for new approaches to ensure long-term treatment goals are met,” said Dr. Robert Zeiser, University Hospital Freiburg, Department of Haematology, Oncology and Stem Cell Transplantation, Freiburg, Germany.

Treatment 52

Treatment Disease Therapies Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

OCTOBER 30, 2020

(NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Cohort 1A: patients not requiring oxygen.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

Drug Discovery World

JULY 2, 2024

Mazzetti and Schneider continue: “The transfer of technologies from the lab to the market, especially in the field of life sciences is no longer purely via IP out licensing, but rather via start-up M&A deals – start-ups being the de-risking vehicle for large corporates, especially in the life sciences and biotherapeutics sector.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

JULY 20, 2023

Drug repurposing in neurological diseases The next speaker was Robert Pitceathly, Honorary Consultant at The National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, London, UK.

Clinical Pharmacology 100

Clinical Pharmacology Clinical Trials Drugs Trials 100

Drug Discovery World

MAY 6, 2024

The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function. In Paris itself, Institut Curie is a major cancer hospital, from which One Biosciences was spun-off.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Since licensed by Ridgeback, all funds used for the development of EIDD-2801/MK-4482 have been provided by Wayne and Wendy Holman and Merck. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

Drug Discovery World

APRIL 20, 2023

Alzheimer’s disease), or by initiating a new one. Drug development opportunities Drugs designed to reduce neuroinflammation are currently in development for a variety of brain diseases. Acute and persistent symptoms in non-hospitalized PCR- confirmed COVID-19 patients,” Sci Rep, vol. depression). F Ceban et al., 93–135, Mar.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

OCTOBER 6, 2021

It is also licensed under the brand name Efluelda ® in Europe where it is indicated for adults aged 60 and older. It is also licensed under the brand name Efluelda® in Europe where it is indicated for adults aged 60 and older. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. How are disease targets selected for challenge trials?

Vaccine 111

Vaccine Trials Disease Virus 111

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

OCTOBER 26, 2020

FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Eli Lilly halted a separate study of its LY-COV555 antibody against COVID-19 in hospitalized patients. FDA Actions. Days after the U.S. Other Industry News.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? There are a lot of drug development challenges that are, in some cases, unique to neuroscience, including neurological diseases, psychiatric disorders, and rare diseases affecting the nervous system.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

AUGUST 3, 2021

. “In the interest of public health and safety, it remains a priority to provide healthcare professionals with as much information as possible about treatment options that may help improve outcomes for patients with severe disease,” said Ilya Yuffa, senior vice president and president of Lilly Bio-Medicines.

Hospitals 52

Hospitals Licensing Licensing FDA 52

The Pharma Data

JANUARY 14, 2021

“Buprenorphine is the most important medication in our arsenal for treating opioid use disorder, which is currently one of the most lethal diseases for Americans.” As a result, some clinicians are hesitant to pursue this DEA license or even engage in treatment of patients with OUD.

Treatment 52

Treatment Licensing Licensing Hospitals 52

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

The Pharma Data

JUNE 7, 2022

The MITT population included all participants who were randomly assigned, received at least one dose of study drug, and were not hospitalized before the first dose of study drug. Since licensed by Ridgeback, all funds used for the development of LAGEVRIO have been provided by Merck and Ridgeback. to 51.7%]; 6.6% to 51.7%]; 6.6%

Hospitals 40

Hospitals Research Laboratories Treatment Disease 40

The Pharma Data

MARCH 8, 2021

Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection. Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

FEBRUARY 12, 2022

This trial was a Phase 2, randomized, clinical trial evaluating treatment of non-hospitalized patients with mild-to-moderate COVID-19 who were treated with the authorized dose of bebtelovimab (175 mg) alone or together with 700 mg bamlanivimab and 1,400 mg of etesevimab. About BLAZE-4.

Treatment 40

Treatment Hospitals FDA Clinical Trials 40

The Pharma Data

APRIL 22, 2023

A public health approach that prioritizes improving access to medications should be adopted, instead of allowing companies to maximize profits,” said Jacob Levi, Intensive Care Medicine, Royal Free Hospital NHS Trust, London, United Kingdom. Millions of lives have been saved by treating infectious diseases at low cost in poor countries.

Medical Schools 40

Medical Schools Licensing Licensing Treatment 40

The Pharma Data

APRIL 27, 2023

RSV causes over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in adults aged 60 years and older each year in Europe. 1 If approved, GSK’s candidate has the potential to be the first vaccine available to help protect older adults from RSV disease. These were typically mild to moderate and transient.

Virus 40

Virus Vaccine Trials Clinical Trials 40

The Pharma Data

NOVEMBER 18, 2020

In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

SEPTEMBER 1, 2021

Since licensed by Ridgeback, all funds used for the development of molnupiravir have been provided by Wayne and Wendy Holman and Merck. Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Data from the study is expected in the second half of 2021.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

The Pharma Data

APRIL 29, 2022

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant, to the Korean Ministry of Food and Drug Safety (KMFDS) following positive Phase III clinical data.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 29, 2020

Y-mAbs Therapeutics has a target action date of November 30 for its Biologics License Application (BLA) for Danyelza (naxitamab) for patients with relapsed/refractory high-risk neuroblastoma. The drug was developed by researchers at Memorial Sloan Kettering Cancer Center and exclusively licensed to Y-mAbs. and Europe.

FDA 52

FDA Licensing Licensing Pharmaceuticals 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. This press release features multimedia. In the U.S.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

MARCH 2, 2021

This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.

Vaccine 52

Vaccine Clinical Trials FDA Hospitals 52

The Pharma Data

JANUARY 17, 2021

The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. On December 17, 2020, Aurinia inked a collaboration and license deal with Japan’s Otsuka Pharmaceutical Co. The NDA was built on data from the Phase III VICTORIA trial.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

FEBRUARY 12, 2022

Baricitinib is an oral, selective Janus kinase (JAK) 1,2 inhibitor used in the treatment of rheumatoid arthritis that has previously shown efficacy in studies of hospitalized adults with COVID-19, including the COV-BARRIER multinational trial with study patients enrolled from 101 sites in 12 countries. under license from Incyte Corp.

Hospitals 40

Hospitals Clinical Trials Licensing Licensing 40

The Pharma Data

APRIL 15, 2022

The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctor’s offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage. The study also showed that, in a population with only 4.2%

FDA 52

FDA Licensing Licensing Production 52

The Pharma Data

MARCH 27, 2022

Food and Drug Administration (FDA) granted priority review for OLUMIANT in severe AA as a potential first-in-disease medicine. “Whether people with alopecia areata suffer loss of all the hair on their body or bald spots and missing eyebrows or eyelashes, this autoimmune disease can be devastating. In February 2022, the U.S.

Licensing 40

Licensing Licensing FDA Approval Disease 40

The Pharma Data

JANUARY 12, 2021

Doses are being supplied for use pursuant to the FDA Emergency Use Authorization for high-risk patients with mild to moderate COVID-19 in order to reduce the risk of progression to severe COVID-19 and/or hospitalization. Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the U.S. Yancopoulos , M.D., In the U.S.

Government 52

Government Hospitals Virus Production 52

The Pharma Data

NOVEMBER 22, 2020

GALACTIC-HF, one of the largest Phase 3 global cardiovascular outcomes trials in heart failure ever conducted, enrolled 8,256 patients who were at risk of hospitalization and death, despite being well treated on standard of care therapy. After a median duration of follow-up of 21.8 After a median duration of follow-up of 21.8

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52